282results about How to "Avoid rapid degradation" patented technology

The present invention comprises: a display unit having a plurality of pixels arranged therein, each pixel including an organic EL element 24, a switching TFT, and a drive TFT; a data signal drive circuit for receiving image data for each frame period and outputting an image signal based on the image data; a scanning signal drive circuit for outputting a scanning signal for controlling a timing at which the switching element of each of the plurality of pixels receives the image signal; and a current source (a light emission power supply unit and a cathode potential control circuit together) for outputting a current supplied to the light emitting unit of each of the plurality of pixels through its drive element; wherein the current source modulates the value of the output current within each frame period.

A method for processing digitized speech signals by analyzing redundant features to provide more robust voice recognition. A primary transformation is applied to a source speech signal to extract primary features therefrom. Each of at least one secondary transformation is applied to the source speech signal or extracted primary features to yield at least one set of secondary features statistically dependant on the primary features. At least one predetermined function is then applied to combine the primary features with the secondary features. A recognition answer is generated by pattern matching this combination against predetermined voice recognition templates.

Methods and compositions are disclosed for the preparation of free radical scavenging polymers and polymer films functionalized with antioxidants. Enzymatic and chemical tailoring of monomers with antioxidants followed by enzymatic polymerization is described. These antioxidant functionalized polymers can increase shelf life and quality of food products, as well as, increase effectiveness of pharmaceutical agents when used as packaging or as coatings on packaging for oxygen sensitive materials. The novel enzymatic covalent coupling of antioxidants to a polymer enhances the free radical scavenging ability of packaging while also inhibiting the escape of the antioxidants, and thus limiting exposure and/or absorption by an individual. In addition to its use in food or pharmaceutical packaging, methods are disclosed for using the antioxidant coupled polymers in a variety of applications including as coatings on the inside of medical devices, such as stents and catheters, which would substantially reduce free radical damage and/or oxygen depletion during medical procedures. Furthermore, through the coupling of antioxidants to biodegradable polymers, controlled delivery and sustained release of an antioxidant to a subject is possible.

Implantable medical devices, more specifically stents, are described herein comprising magnesium based core structures whose elimination times are slowed by the appropriate polymer coating. Appropriate biodegradable polymers are selected which are suitable to provide a specific degradation time for the magnesium based core structure. Bioactive agents are incorporated into the polymer coating in order to aid in the therapeutic effect of the stent.

The present invention provides methods and compositions for stabilizing dried nucleic acids with carbohydrates such as non-reducing sugars, polysaccharides, and reducing sugars. Preferably, the stabilized nucleic acids are coated on a microprojection member for transdermal delivery. The invention further provides compositions and methods that involve the use of DNase inhibitors to stabilize dried nucleic acids delivered directly into bodily tissues.

A formed in-place spinal implant comprising a hardenable, resorbable, bone fusion-promoting composition, wherein the implant may be rigidly connected to adjacent vertebrae until fusion occurs.

A stent comprising a matrix and a fiber reinforcement about which the matrix is chemically or mechanically attached. The matrix is provided with heavier loads of pharmaceutically active ingredients or genetic materials as a result of the increased strength and mechanical characteristics provided to the stent by the fiber reinforcement. The fiber reinforcement can be comprised of a plurality of mono-filament fibers spaced and oriented in a flat weave pattern to which the matrix is chemically or mechanically attached. Degradation rates of the materials that comprise the matrix and the fiber reinforcement can be varied to vary the time period in which the stent maintains its mechanical characteristics or releases the pharmaceutically active ingredients or genetic materials therefrom. Multiple stage release profiles can be provided by providing multiple layers of matrices and fiber reinforcements, whereby different pharmaceutically active ingredients or genetic materials or different concentrations thereof, can be released according to the degradation profiles of the matrix and fiber reinforcment.

Composite material having carbon fibers embedded in a polymeric matrix comprising a thermoset resin, where the carbon fibers are precoated with a sizing agent comprising a saturated polyurethane or polyhydroxyether before being embedded in the resin. The invention also contemplates processes for making this composite material and intermediate products thereof.

The invention relates to dose escalation enzyme replacement therapy using acid sphingomyelinase (ASM) for the treatment of human subjects having acid sphingomyelinase deficiency (ASMD), and, in particular, patients with non-neurological manifestations of Niemann-Pick Disease (NPD), and in certain embodiments, NPD type B.

Stabilized controlled release pharmaceutical preparations are disclosed in which active ingredient degradation is prevented without the use of a stabilizer. The active ingredient is sealed away from excipients that can adversely affect stability by sealing the excipients rather than the active ingredient. The preparations are substantially unaffected by exposure to storage conditions of elevated temperature and/or elevated relative humidity.

An implant made in total or in parts of a biodegradable magnesium alloy consisting of Y: 2.0-6.0% by weight, Nd: 1.5-4.5% by weight, Gd: 0-4.0% by weight, Dy: 0-4.0% by weight. Er: 0-4.0% by weight, Zr: 0.1-1.0% by weight, Li:0-0.2% by weight, Al: 0-0.3% by weight, under the condition that a) a total content of Er, Gd and Dy is in the range of 0.5-4.0% by weight and b) a total content of Nd, Er, Gd and Dy is in the range of 2.0-5.5% by weight, the balance being magnesium and incidental impurities up to a total of 0.3% by weight.

Antibody formulations are described comprising a mixture of an anti-α4β7 antibody, an antioxidant or chelator, and at least one free amino acid. The disclosed formulations may have improved stability, reduced aggregate formation, or both. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-α4β7 antibody in vivo.

A Plasma torch (10) for microwave induced plasma spectrochemical analysis of a sample includes a nozzle (30) in an inlet (18) for the main plasma gas flow between outer tube (12) and intermediate tube (14) of the torch (10). The nozzle (30) increases the gas flow velocity in the sheathing gas layer for the plasma which is provided by the gas flow from the annular gap (22) between the tubes (12 and 14). The increased velocity of the gas in the sheathing gas layer “stiffens” that layer and thus better confines the microwave induced plasma (such better confinement not being necessary for an ICP torch). Thus the torch is of improved durability for a microwave induced plasma compared to an ICP torch. The sample injection (inner) tube (16) may have a reduced diameter outlet at its end (34) which is substantially level with the end (35) of intermediate tube (14) to improve injection of a sample into the microwave induced plasma. The inlet end (26) of the sample injection tube (16) may include a heater (36) to assist in preventing blockages in tube (16) near its outlet end.

Nanoparticle-amphiphilic polymer complexes for nucleic acid delivery and real-time imaging.

A process for recycling a polymer blend necessarily containing PLA, comprising grinding, compacting, dissolving in a solvent of PLA, removing the undissolved contamining polymers, alcoholysis depolymerisation reaction and purification steps.

A process for recycling a polymer blend necessarily containing PLA, comprising grinding, compacting, dissolving in a solvent of PLA, removing the undissolved contamining polymers, alcoholysis depolymerisation reaction and purification steps.

The print head is scanned over a printing medium in a sub-scanning direction different from a direction in which the nozzles are arranged. The printing medium is conveyed by a predetermined amount K (where K=a×L (a is a natural number and L is the size of the gradation patterns in the direction in which the nozzles are arranged) or K=L/b (b is a natural number)) in a direction in which the nozzles are arranged, between a preceding scan and a next scan of the print head. Correspondences between image data and the plurality of nozzles are shifted in the direction in which the nozzles are arranged. The operated dot patterns are changed so as to allow the selective use of a plurality of different dot patterns indicating the same gradation value.